Shopping Cart
Remove All
Your shopping cart is currently empty
AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $59 | In Stock | In Stock | |
| 5 mg | $165 | In Stock | In Stock | |
| 10 mg | $243 | In Stock | In Stock | |
| 25 mg | $397 | In Stock | In Stock | |
| 50 mg | $597 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $195 | In Stock | In Stock |
| Description | AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies. |
| Targets&IC50 | CDK9:4 nM (IC50) |
| In vitro | Short-term administration of AZD4573 induced a swift, dose- and time-dependent reduction in cellular pSer2-RNAPII levels, which in turn activated caspase 3, leading to apoptosis across a wide spectrum of hematological cancer cell lines. Notably, caspase activation exhibited an EC50 of 13.7 nM in the acute myeloid leukemia model MV4-11. |
| In vivo | AZD4573 demonstrates a short half-life (<1 hour) in multiple species (dog, rat, monkey) and possesses good solubility for intravenous administration. |
| Molecular Weight | 429.94 |
| Formula | C22H28ClN5O2 |
| Cas No. | 2057509-72-3 |
| Smiles | CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1cc(-c2cnn3CC(C)(C)Cc23)c(Cl)cn1 |
| Relative Density. | 1.39 g/cm3 (Predicted) |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 125 mg/mL (290.74 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (9.3 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.